S Schryber - Concepedia

Author

S Schryber

Dana-Farber Cancer Institute

Also Known As

S M Schryber, S Schryber, S. M. Schryber, S. Schryber, Susan M. Schryber, Susan Schryber

Publications

535

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Press Beth Israel Deaconess Hospital

About

S Schryber is an author at Dana-Farber Cancer Institute specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	470
2	Health Sciences	4	4	219
3	Immunology	3	3	172
4	Cellular Therapies	2	2	198
5	Hepatology	1	1	47

S Schryber

Publications

524

Citations

H-Index

Page 1

	Year	Citations
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. Joseph P. Eder, Karen H. Antman, W. P. Peters, Journal of Clinical Oncology Metastatic Breast CancerOncologyAgent ChemotherapyBreast OncologyBone Marrow Harvest	1986	130
High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. W. P. Peters, Joseph P. Eder, W. David Henner, Journal of Clinical Oncology Cell TherapyPharmacotherapyHigh-dose CombinationExcessive RenalRegenerative Medicine	1986	121
A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. Joseph P. Eder, Anthony Elias, Thomas C. Shea, Journal of Clinical Oncology Cell TherapyImmunologySolid Tumor PatientsCell Replacement TherapyPharmacotherapy	1990	77
Cyclophosphamide and Thiotepa With Autologous Bone Marrow Transplantation in Patients With Solid Tumors Joseph P. Eder, Karen H. Antman, Anthony Elias, JNCI Journal of the National Cancer Institute Solid TumorsImmunologyPathologyCell Replacement TherapyPharmacotherapy	1988	50
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Karen H. Antman, Joseph P. Eder, Alby Elias, PubMed PharmacotherapyHigh-dose CombinationTransplant DoseMetronomic TherapyHematology	1987	47
A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. Anthony Elias, Lois Ayash, Joseph P. Eder, Journal of Clinical Oncology Peak CreatinineImmunologyPharmacotherapyMetronomic ChemotherapyDose-limiting Toxicity	1991	45
High-dose thiotepa alone and in combination regimens with bone marrow support. Karen H. Antman, Joseph P. Eder, Alby Elias, PubMed	1990	37
Endogenous Digoxin-Like Immunoreactive Factor and Digitalislike Factor Associated with the Hypertension of Patients Receiving Multiple Alkylating Agents as Part of Autologous Bone Marrow Transplantation Steven W. Graves, J. P. Eder, S Schryber, Clinical Science	1989	17

Page 1